






Medical/Pharmacy program continued with UMR/RxBenefits
Added UHC Select Network Plan
Continued Zero program
Dental program continued with Delta Dental
Vision Program continued with VSP
Continued TeleHealth program
Moved EAP from Anthem to Optum










- · The medical/pharmacy program is experiencing an improved claims year due to a lower incidence and severity of large ("catastrophic") claimants
 - 2021 5 claimants \$1.44m paid
 - 2022 4 claimants \$600k paid
- Due to prudent budgeting, the medical program currently has an adequate reserve to offset unexpected costs

7





Projected Trend Costs Figure B: Health plans and employers expect spending in 2022 to be higher than what would have been expected in 2022 before the pandemic

10



Regenexx Regenerative treatment for those with orthopedic issues using stem cell therapy, provides patients alternate choice to surgery · ROI analysis shows on average greater than 80% reduction in orthopedic surgical spending · Currently considered investigational · Negative effects of surgery: Poor results, revisions, progression, complications (blood clots, stroke, nerve damage) · Harms healthy tissue · Opioid addiction Absenteeism

12 11

2

